This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2005;366(9496):1507-8.

doi: 10.1016/S0140-6736(05)67608-8.

Molecular targeted therapy for lung cancer

Amir Onn¹, Roy S Herbst

Affiliations

PMID: 16257327
DOI: 10.1016/S0140-6736(05)67608-8

Comment

Molecular targeted therapy for lung cancer

Amir Onn et al. Lancet. 2005.

. 2005;366(9496):1507-8.

doi: 10.1016/S0140-6736(05)67608-8.

Authors

Amir Onn¹, Roy S Herbst

Affiliation

¹ Pulmonary Medicine and Cancer Biology, MD Anderson Cancer Center, Houston, TX 77030, USA. amironn@mdanderson.org

PMID: 16257327
DOI: 10.1016/S0140-6736(05)67608-8

Erratum in

Lancet. 2005 Nov 26;366(9500):1848

No abstract available

PubMed Disclaimer

Comment on

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).
Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K. Thatcher N, et al. Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37. doi: 10.1016/S0140-6736(05)67625-8. Lancet. 2005. PMID: 16257339 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information